Detalhe da pesquisa
1.
Treatment with the glucagon receptor antagonist LY2409021 increases ambulatory blood pressure in patients with type 2 diabetes.
Diabetes Obes Metab
; 19(8): 1071-1077, 2017 08.
Artigo
Inglês
| MEDLINE | ID: mdl-28191913
2.
Once-Weekly Basal Insulin Fc Demonstrated Similar Glycemic Control to Once-Daily Insulin Degludec in Insulin-Naive Patients With Type 2 Diabetes: A Phase 2 Randomized Control Trial.
Diabetes Care
; 46(5): 1060-1067, 2023 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36944059
3.
Novel Once-Weekly Basal Insulin Fc Achieved Similar Glycemic Control With a Safety Profile Comparable to Insulin Degludec in Patients With Type 1 Diabetes.
Diabetes Care
; 46(5): 1052-1059, 2023 05 01.
Artigo
Inglês
| MEDLINE | ID: mdl-36920867
4.
Coding variants in PNPLA3 and TM6SF2 are risk factors for hepatic steatosis and elevated serum alanine aminotransferases caused by a glucagon receptor antagonist.
Hepatol Commun
; 2(5): 561-570, 2018 May.
Artigo
Inglês
| MEDLINE | ID: mdl-29761171
5.
Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies.
Diabetes Care
; 39(7): 1241-9, 2016 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-26681715
6.
Erratum. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 40(6): 808, 2017 06.
Artigo
Inglês
| MEDLINE | ID: mdl-28420698
7.
Response to Comment on Kazda et al. Evaluation of Efficacy and Safety of the Glucagon Receptor Antagonist LY2409021 in Patients With Type 2 Diabetes: 12- and 24-Week Phase 2 Studies. Diabetes Care 2016;39:1241-1249.
Diabetes Care
; 39(11): e199-e200, 2016 11.
Artigo
Inglês
| MEDLINE | ID: mdl-27926898